Fig. 7

DESC1 inhibited chemotherapy resistance of ESCC cells via EGFR/AKT. EC9706 or KYSE30 cells were divided into four groups: si-NC, si-DESC1, si- DESC1 + DMSO, and si-DESC1 + AST1306 (EGFR inhibitor, 1 μM,24 h) groups. a After the treatment of cisplatin (0, 1, 2, 4, 8, 16 μM) for 48 h, si-DESC1 promoted chemotherapy resistance of ESCC cells, while AST1306 reversed this effect. b After the treatment of 5-Fu (0, 1, 4, 16, 32, 64 μM) for 48 h, si-DESC1 promoted chemotherapy resistance of ESCC cells, while AST1306 reversed this effect. c si-DESC1 upregulated the expressions of EGFR and p-AKT, while AST1306 reversed this effect